nach oben

Erschienen in:

01.09.2015 | Research

Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma

verfasst von: Osamu Nikkuni, Kyoichi Kaira, Minoru Toyoda, Masato Shino, Koichi Sakakura, Katsumasa Takahashi, Hideyuki Tominaga, Noboru Oriuchi, Masami Suzuki, Misa Iijima, Takayuki Asao, Masahiko Nishiyama, Shushi Nagamori, Yoshikatsu Kanai, Tetsunari Oyama, Kazuaki Chikamatsu

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to evaluate the clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with advanced laryngeal squamous cell carcinoma (LSCC). A total of 73 patients with advanced LSCC were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, 4F2hc, system ASC amino acid transporter-2 (ASCT2), cell proliferation by Ki-67, microvessel density (MVD) determined by CD34 and p53. A positive LAT1, 4F2hc and ASCT2 expression (staining more than a quarter) in the primary sites were recognized in 85, 80 and 45 %, respectively, and a high LAT1, 4F2hc and ASCT2 expression (staining more than a half) yielded 48, 31 and 18 %, respectively. High expression of LAT1 was significantly associated with lymph node metastasis, 4F2hc, ASCT2, Ki-67 and p53. The expression of LAT1 was significantly correlated with ASCT2, 4F2hc, cell proliferation, and MVD. By univariate analysis, there was no statistically significant relationship between LAT1 expression and prognosis in advanced LSCC. LAT1, 4F2hc and ASCT2 were highly expressed in patients with advanced laryngeal cancer. Our study suggests that the expression of LAT1 plays a crucial role in the metastasis and tumor progression in advanced LSCC.

Nur mit Berechtigung zugänglich

Ragin CC, Modugno F, Gollin SM (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86:104–114CrossRefPubMed

Thephamongkhol K, Browman G, Hodson I, Oliver T, Zuraw L, members of the Head and Neck Cancer Disease Site Group (2004) Chemotherapy with radiotherapy for nasopharygeal cancer: a clinical practice guidelineevidence-based Series #5-7. Cancer Care Ontario, Program in Evidence-Based Care, Toronto

Christensen HN (1990) Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70:43–77PubMed

Fuchs BC, Bode BP (2006) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254–266CrossRef

Kanai Y, Segawa H, Miyamoto K et al (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629–23632CrossRefPubMed

Yanagida O, Kanai Y, Chairoungdua A et al (2001) Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514:291–302CrossRefPubMed

Nawashiro H, Otani N, Shinomiya N et al (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119:484–492CrossRefPubMed

Kim CS, Cho SH, Chun HS et al (2008) BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31:1096–1100CrossRefPubMed

Kim CS, Moon IS, Park JH et al (2010) Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells. Biol Pharm Bull 33:1117–1121CrossRefPubMed

10.

Kekuda R, Prasad PD, Fei YJ et al (1996) Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line. J Biol Chem 271:18657–18661CrossRefPubMed

11.

Fuch BC, Finger RE, Onan MC et al (2007) ASCT2 silencing regulates mammalian target of rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 293:C55–C63CrossRef

12.

Kobayashi H, Ishii Y, Takayama T (2005) Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90:233–238CrossRefPubMed

13.

Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98:742–748PubMedCentralCrossRefPubMed

14.

Nakanishi K, Ogata S, Matsuo H et al (2007) Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451:681–690CrossRefPubMed

15.

Sakata T, Ferdous G, Tsuruta T et al (2009) L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59:7–18CrossRefPubMed

16.

Ichinoe M, Mikami T, Yoshida T et al (2011) High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 61:281–289CrossRefPubMed

17.

Furuya M, Horiguchi J, Nakajima H et al (2012) Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 103:382–389CrossRefPubMed

18.

Kaira K, Oriuchi N, Takahashi T et al (2011) LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 3:468–478PubMedCentralPubMed

19.

Kaira K, Sunose Y, Arakawa K et al (2012) Prognostic significance of L-type amino acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 107:632–638PubMedCentralCrossRefPubMed

20.

Shimizu K, Kaira K, Tomizawa Y et al (2014) ASC amino acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer 110:2030–2039PubMedCentralCrossRefPubMed

21.

Toyoda M, Kaira K, Ohshima Y et al (2014) Prognostic significance of amino acid transporter expression (LAT1, ASCT2 and xCT) in surgically resected tongue cancer. Br J Cancer 110:2506–2513PubMedCentralCrossRefPubMed

22.

Li R, Younes M, Frolov A et al (2003) Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 23:3413–3418PubMed

23.

Whitte D, Ali N, Carlson N et al (2002) Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 22:2555–2557

24.

Kaira K, Oriuchi N, Imai H et al (2009) CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol 16:3473–3481CrossRefPubMed

25.

Kaira K, Oriuchi N, Imai H et al (2009) Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 66:120–126CrossRefPubMed

26.

Namikawa M, Kakizaki S, Kaira K, et al (2014) Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res in press

27.

Hassanein M, Hoeksema MD, Shiota M et al (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 19:560–570PubMedCentralCrossRefPubMed

28.

Imai H, Kaira K, Oriuchi N et al (2010) Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 30:4819–4828PubMed

Titel: Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma
verfasst von: Osamu Nikkuni
Kyoichi Kaira
Minoru Toyoda
Masato Shino
Koichi Sakakura
Katsumasa Takahashi
Hideyuki Tominaga
Noboru Oriuchi
Masami Suzuki
Misa Iijima
Takayuki Asao
Masahiko Nishiyama
Shushi Nagamori
Yoshikatsu Kanai
Tetsunari Oyama
Kazuaki Chikamatsu
Publikationsdatum: 01.09.2015
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2015
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-015-9954-3

Springer Medizin

Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Computer Aided Semi-Automated Evaluation of HER2 Immunodetection—A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy

Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study

Apoptosis Phenomena in Squamous Cell Carcinomas and Adenocarcinomas of the Uterine Cervix

Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer

Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity- An in silico Approach

Regional Disease Control in Selected Patients with Sentinel Lymph Node Involvement and Omission of Axillary Lymph Node Dissection

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie